


Dieter Schollmeyer,^a Bernd
Kammerer,^b Christian Peifer^{b*}
and Stefan Laufer^b^aInstitut für Organische Chemie der Universität
Mainz, Duesbergweg 10-14, D-55099 Mainz,
Germany, and ^bPharmazeutisches Institut, Auf
der Morgenstelle 8, Universität Tübingen, 72076
Tübingen, GermanyCorrespondence e-mail:
christian.peifer@uni-tuebingen.de

Key indicators

Single-crystal X-ray study
T = 295 K
Mean $\sigma(\text{C}-\text{C}) = 0.005 \text{ \AA}$
R factor = 0.041
wR factor = 0.115
Data-to-parameter ratio = 14.7For details of how these key indicators were
automatically derived from the article, see
<http://journals.iucr.org/e>.(3*RS*,1*SR*)-3-Bromo-3-(1-phenylpropyl)chroman-
2,4-dioneThe title compound, C₁₈H₁₅BrO₃, was obtained by bromination of phenprocoumon with *N*-bromosuccinimide. The X-ray structure confirms an earlier proposal concerning the regioselectivity of the reaction to introduce the Br atom at the 3-position.

Comment

The title compound, (I), was prepared in an approach to synthesize possible metabolites of phenprocoumon, a well known antithrombotic compound (Hirsh *et al.*, 2001). In order to compare the fragmentation pattern of an unknown metabolite (He *et al.*, 1999) in human urine with a chemically synthesized compound by mass spectrometry (MS) techniques, we decided to introduce bromine into the 3-position of phenprocoumon. Analytical data obtained by TLC, IR, ¹H NMR and ¹³C NMR supported the expected structure of (I). However, by performing gas chromatography(GC)/MS analysis of (I), no isotopic pattern of a bromine-containing compound in the spectrum could be detected in the spectrum. Furthermore, no difference between phenprocoumon and (I) concerning both retention time and fragmentation pattern was observed, indicating decomposition of (I) to the starting material as a measurement artifact. Additionally, use of the electrospray ionization (ESI)-MS technique as a soft ionization method revealed unexpectedly no bromine. We now report the X-ray crystal structure analysis which definitively proved the structure of (I).Received 19 January 2005
Accepted 25 February 2005
Online 11 March 2005

structure of (I) consists of enantiomers of one diastereomer. Since the other diastereomer was not detected, we conclude that the approach of bromine to the 3-position of phenprocoumone takes place on the same side as the proton (and opposite to the bulky phenyl group), yielding only the racemic mixture of enantiomers of one possible pair of diastereomers. The molecules are linked by C—H···O hydrogen bonds (Table 2) to form a dimer. This also leads to a rather short C5···Br1(−*x*, −*y*, −*z*) contact [3.292 (4) Å].

Experimental

Phenprocoumone (2.5 mmol) was stirred with *N*-bromosuccinimide (2.75 mmol) in dry chloroform for 2 h at room temperature. The mother liquor was evaporated and the residue purified by silica-gel column chromatography (ethyl acetate–hexane = 1:5) to yield (I) quantitatively (Hegedüs, 1958). Crystals of (I) precipitated at 278 K from acetone solution by slow evaporation.

Crystal data

$C_{18}H_{15}BrO_3$	$Z = 2$
$M_r = 359.21$	$D_x = 1.540 \text{ Mg m}^{-3}$
Triclinic, $P\bar{1}$	Cu $K\alpha$ radiation
$a = 6.2769 (16) \text{ \AA}$	Cell parameters from 25 reflections
$b = 8.6095 (10) \text{ \AA}$	$\theta = 60\text{--}71^\circ$
$c = 14.775 (3) \text{ \AA}$	$\mu = 3.70 \text{ mm}^{-1}$
$\alpha = 91.154 (12)^\circ$	$T = 295 (2) \text{ K}$
$\beta = 90.796 (18)^\circ$	Plate, colourless
$\gamma = 103.908 (14)^\circ$	$0.38 \times 0.28 \times 0.02 \text{ mm}$
$V = 774.7 (3) \text{ \AA}^3$	

Data collection

Enraf–Nonius CAD-4 diffractometer	$R_{\text{int}} = 0.043$
$\omega/2\theta$ scans	$\theta_{\text{max}} = 73.1^\circ$
Absorption correction: numerical (de Meulenaer & Tompa, 1965)	$h = -7 \rightarrow 7$
$T_{\text{min}} = 0.353$, $T_{\text{max}} = 0.926$	$k = -10 \rightarrow 10$
3234 measured reflections	$l = -18 \rightarrow 0$
3109 independent reflections	3 standard reflections
2812 reflections with $I > 2\sigma(I)$	frequency: 60 min
	intensity decay: 10%

Refinement

Refinement on F^2	$w = 1/[\sigma^2(F_o^2) + (0.0656P)^2 + 0.3708P]$
$R[F^2 > 2\sigma(F^2)] = 0.041$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.115$	$(\Delta/\sigma)_{\text{max}} < 0.001$
$S = 1.12$	$\Delta\rho_{\text{max}} = 0.57 \text{ e \AA}^{-3}$
3109 reflections	$\Delta\rho_{\text{min}} = -0.57 \text{ e \AA}^{-3}$
212 parameters	
Only H-atom U 's refined	

Table 1

Selected geometric parameters (Å, °).

Br1—C1	1.992 (3)		
C2—C1—Br1	100.32 (18)	C10—C1—Br1	101.28 (18)
C13—C1—Br1	111.1 (2)		
Br1—C1—C13—C14	−175.2 (2)		




Figure 1

The molecular structure of (I), showing displacement ellipsoids at the 50% probability level.

Table 2

Hydrogen-bonding geometry (Å, °).

<i>D</i> —H··· <i>A</i>	<i>D</i> —H	H··· <i>A</i>	<i>D</i> ··· <i>A</i>	<i>D</i> —H··· <i>A</i>
C4—H4···O11 ⁱ	0.93	2.54	3.372 (4)	150

Symmetry code: (i) −*x*, 1 − *y*, −*z*.

H atoms were positioned geometrically and allowed to ride during subsequent refinement, with C—H = 0.93–0.96 Å and with torsional freedom for the methyl group. The $U_{\text{iso}}(\text{H})$ parameters were refined without restraints. For methyl and methylene H atoms one U_{iso} parameter per group was refined. The methyl group could rotate around the C—C bond.

Data collection: *CAD-4 Software* (Nonius, 1998); cell refinement: *CAD-4 Software*; data reduction: *CORINC* (Dräger & Gattow, 1971); program(s) used to solve structure: *SIR92* (Altomare *et al.*, 1994); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEPII* (Johnson, 1976); software used to prepare material for publication: *SHELXL97*.

References

- Altomare, A., Casciarano, G., Giacovazzo, C., Guagliardi, A., Burla, M. C., Polidori, G. & Camalli, M. (1994). *J. Appl. Cryst.* **27**, 435.
 Dräger, M. & Gattow, G. (1971). *Acta Chem. Scand.* **25**, 761–762.
 Nonius (1998). *CAD-4 Software*. Nonius BV, Delft, The Netherlands.
 He, M., Korzekwa, K. R., Jones, J. P., Rettie, A. E. & Trager, W. F. (1999). *Arch. Biochem. Biophys.* **372**, 16–28.
 Hegedüs, B. (1958). Switzerland Patent No. CH 329573.
 Hirsh, J., Dalen, J., Anderson, D. R., Poller, L., Bussey, H. & Ansell, J. (2001). *Chem.* **119**, 8–21.
 Johnson, C. K. (1976). *ORTEPII*. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
 Meulenaer, J. de & Tompa, H. (1965). *Acta Cryst.* **19**, 1014–1018.
 Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.